Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for healthcare investments at Saunders, Karp & Megrue. He was also involved in founding several US biotechnology companies and was the first investor in and acting CEO of UpToDate, Inc.

Steve previously worked as an Investigator of the Howard Hughes Medical Institute at Yale and was an Associate Physician at Brigham and Women’s Hospital. He has published extensively on the molecular genetics of human disease. Steve practiced medicine at the John Radcliffe, Churchill, Guys, St. Thomas’s, and Hammersmith Hospitals and the Institute of Neurology, Queen Square before taking up research at Oxford University. He holds a BA in Natural Sciences from Cambridge and an DM from Oxford.

Steve is a member of the board of eZono AG, Vital Connect, Inc., and AccuVein, Inc. He was previously a director of Ambio, Inc., Beacon Endoscopic Ltd, BioVex Group, Inc., Cara Therapeutics, Inc., Cheetah Medical Inc., Clavis AS., Gendaq Ltd, Momenta Pharmaceuticals, Inc., Pulmagen Therapeutics Ltd., Sangamo Biosciences, Inc., UpToDate, Inc., Vascular Pathways, Inc., Xention Ltd., Patient Connect Ltd and Zipline Medical, Inc.

Latest news

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]

MVM invests in Vero Biotech
December 15, 2021

VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]

MVM Invests In Optinose
November 18, 2021

MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]

Paragon 28, Inc. Announces Pricing of Initial Public Offering
October 15, 2021

ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]

MVM invests in InBrace
September 8, 2021

MVM invested $15 million in InBrace. InBrace is an orthodontic company that created the novel SmartwireTM, a new category in […]

Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
August 6, 2021

Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the […]

Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021

Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]